Recurrent respiratory papillomatosis: role of bevacizumab and HPV vaccination. A literature review with case presentations
References
- Andrei EC, Baniţă IM, Munteanu MC, Busuioc CJ, Mateescu GO, Mălin RD, et al. Oral papillomatosis: its relation with human papilloma virus infection and local immunity - an update. Medicina (Kaunas) 2022; 58: 1103. doi: 10.3390/medicina58081103
- Betz SJ. HPV-related papillary lesions of the oral mucosa: a review. Head Neck Pathol 2019; 13: 80-90. doi: 10.1007/s12105-019-01003-7
- Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-54. doi: 10.1016/j.vaccine.2012.05.070
- Syrjänen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol 2003; 192: 123-8. doi: 10.1007/s00430-002-0173-7
- Welschmeyer A, Berke G S. An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2021; 6: 226-33. doi: 10.1002/lio2.521
- Wang HFan, Wang SS, Tang YJ, Chen Y, Zheng M, Tang YL, et al. The double-edged sword-how human papillomaviruses interact with immu-nity in head and neck cancer. Front Immunol 2019; 10: 653. doi: 10.3389/fimmu.2019.00653
- Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses 2017; 9: 229. doi: 10.3390/v9080229
- Langer C, Wittekindt C, Wolf G. [Recurrent respiratory papillomatosis: current information on diagnosis and therapy]. [German]. Onkol up2date 2020; 2: 107-18. doi: 10.1055/a-1132-0051
- San Giorgi MRM, van den Heuvel ER, Tjon Pian Gi REA, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol 2016; 41: 448-53. doi: 10.1111/coa.12565
- Evers G, Schliemann C, Beule A, Schmidt LH, Schulze AB, Kessler C, et al. Long-term follow-up on systemic bevacizumab treatment in recurrent res-piratory papillomatosis. Laryngoscope 2021; 131: E1926-E33. doi: 10.1002/lary.29351
- Seedat RY. Juvenile-onset recurrent respiratory papillomatosis diagnosis and management – a developing country review. Pediatr Heal Med Ther 2020; 11: 39-46. doi: 10.2147/PHMT.S200186
- Ouda AM, Elsabagh AA, Elmakaty IM, Gupta I, Vranic S, Hamda Al-Thawadi H, et al. HPV and recurrent respiratory papillomatosis: a brief review. Life 2021; 11: 1-17. doi: 10.3390/life11111279
- Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med 2017; 126: 116.21. doi: 10.1016/j.rmed.2017.03.030
- Mauz P S, Zago M, Kurth R, Pawlita M, Holderried M, Thiericke J, et al. A case of recurrent respiratory papillomatosis with malignant transformation, HPV11 DNAemia, high L1 antibody titre and a fatal papillary endocardial lesion. Virol J 2014; 11: 1-6. doi: 10.1186/1743-422X-11-114
- Bertino G, Pedretti F, Mauramati S, Filauro M, Vallin A, Mora F, et al. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study. Acta Otorhinolaryngol Ital 2023; 43: S111-S122. doi: 10.14639/0392-100X-suppl.1-43-2023-14
- Torres-Canchala L, Cleves-Luna D, Arias-Valderrama O, Candelo E, Guerra MA, Pachajoa H, et al. Systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022. Child 2022; 10: 54. doi: 10.3390/children10010054
- Derkay CS, Wikner EE, Pransky S, Best SR, Zur K, Sidell DR, et al. Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why? Laryngoscope 2023; 133: 2-3. doi: 10.1002/lary.30180
- Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel RNPM. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol 2022; 279: 4229-40. doi: 10.1007/s00405-022-07388-6
- Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005; 114: 463-71. doi: 10.1177/000348940511400608
- Bergler WF, Götte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2000; 257: 263-9. doi: 10.1007/s004050050236
- Patel A, Orban N. Infantile recurrent respiratory papillomatosis: review of adjuvant therapies. J Laryngol Otol 2021; 135: 958-63. doi: 10.1017/S0022215121002322
- Tjon Pian GiREA, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, et al. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®). Eur Arch Otorhinolaryngol 2012; 269: 361-2. doi: 10.1007/s00405-011-1804-7
- Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005; 114: 289-95. doi: 10.1177/000348940511400407
- Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 2014; 8: 1912-8 doi: 10.3892/ol.2014.2486
- Ryan MA, Leu GR, Upchurch PA, Tunkel DE, Walsh JM, Boss EF, et al. Systemic bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021; 131: 1138-46. doi: 10.1002/lary.29084
- Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 2011; 120: 627-34. doi: 10.1177/000348941112001001.
- Zagzoog FH, Mogharbel AM, Alqutub A, Bukhari M, Almohizea MI. Intralesional cidofovir vs. bevacizumab for recurrent respiratory pap-illomatosis: a systematic review and indirect meta-analysis. Eur Arch Otorhinolaryngol 2024; 281: 601-27. doi: 10.1007/s00405-023-08279-0
- Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J. Voice 2015; 29: 223-9. doi: 10.1016/j. jvoice.2014.08.003
- Mau T, Amin MR, Belafsky PC, Best SR, Friedman AD, Klein AM, et al. Interim results of a phase 1/2 open-label study of INO-3107 for HPV-6 and/or HPV-11-associated recurrent respiratory papillomatosis. Laryngoscope 2023; 133: 3087-93. doi: 10.1002/lary.30749
- Nagel S, Busch C, Blankenburg T, Schütte W. [Treatment of respiratory papillomatosis − a case report on systemic treatment with bevacizumab]. [German]. Pneumologie 2009; 63: 387-9. doi: 10.1055/s-0029-1214714
- Best S R, Mohr M, Zur K. B. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope 2017; 127: 2225-9. doi: 10.1002/lary.26662
- Allen CT. Biologics for the treatment of recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012; 54: 769-77. doi: 10.1016/j.otc.2021.05.002
- Yiu Y, Fayson S, Smith H, Matrka L. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2019; 128: 309-15. doi: 10.1177/0003489418821695
- Chirilǎ M, Bolboacǎ SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2014; 271: 1135-42. doi: 10.1007/s00405-013-2755-y
Language: English
Page range: 23 - 30
Submitted on: Nov 3, 2024
Accepted on: Nov 26, 2024
Published on: Feb 27, 2025
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2025 Silvio Sporeni, Francesca Rifaldi, Irene Lanzetta, Ilaria Imarisio, Benedetta Montagna, Francesco Serra, Francesco Agustoni, Paolo Pedrazzoli, Marco Benazzo, Giulia Bertino, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.